AAAAAA

   
Results: 1-7 |
Results: 7
Phase I trial of escalating doses of paclitaxel combined with fixed doses of cisplatin and doxorubicin in advanced endometrial cancer and other gynecologic malignancies: A Gynecologic Oncology Group Study
Authors: Fleming, GF Fowler, JM Waggoner, SE Copeland, LJ Greer, BE Horowitz, I Sutton, G Schilder, RJ Fracasso, PM Ball, HG McGuire, WP
Citation: Gf. Fleming et al., Phase I trial of escalating doses of paclitaxel combined with fixed doses of cisplatin and doxorubicin in advanced endometrial cancer and other gynecologic malignancies: A Gynecologic Oncology Group Study, J CL ONCOL, 19(4), 2001, pp. 1021-1029
Phase I trial of multiple cycles of high-dose carboplatin, paclitaxel, andtopotecan with peripheral-blood stem-cell support as front-line therapy
Authors: Schilder, RJ Gallo, JM Millenson, MM Bookman, MA Weiner, LM Rogatko, A Rogers, B Padavic-Shallers, K Boente, M Rosenblum, N Adams, AL Ciccotto, S Ozols, RF
Citation: Rj. Schilder et al., Phase I trial of multiple cycles of high-dose carboplatin, paclitaxel, andtopotecan with peripheral-blood stem-cell support as front-line therapy, J CL ONCOL, 19(4), 2001, pp. 1183-1194
Phase II trial of induction high-dose chemotherapy followed by surgical resection and radiation therapy for patients with marginally resectable non-small cell carcinoma of the lung
Authors: Schilder, RJ Goldberg, M Millenson, MM Movsas, B Rogatko, A Rogers, B Langer, CJ
Citation: Rj. Schilder et al., Phase II trial of induction high-dose chemotherapy followed by surgical resection and radiation therapy for patients with marginally resectable non-small cell carcinoma of the lung, LUNG CANC, 27(1), 2000, pp. 37-45
Evaluation of gemcitabine in patients with squamous cell carcinoma of the cervix: A Phase II study of the Gynecologic Oncology Group
Authors: Schilder, RJ Blessing, JA Morgan, M Mangan, CE Rader, JS
Citation: Rj. Schilder et al., Evaluation of gemcitabine in patients with squamous cell carcinoma of the cervix: A Phase II study of the Gynecologic Oncology Group, GYNECOL ONC, 76(2), 2000, pp. 204-207
Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with Zevalin, a Y-90-labeled anti-CD20 monoclonal antibody
Authors: Wiseman, GA White, CA Witzig, TE Gordon, LI Emmanouilides, C Raubitschek, A Janakiraman, N Gutheil, J Schilder, RJ Spies, S Silverman, DHS Grillo-Lopez, AJ
Citation: Ga. Wiseman et al., Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with Zevalin, a Y-90-labeled anti-CD20 monoclonal antibody, CLIN CANC R, 5(10), 1999, pp. 3281S-3286S
Phase I trial of multiple cycles of high-dose chemotherapy supported by autologous peripheral-blood stem cells
Authors: Schilder, RJ Johnson, S Gallo, J Kindsfather, S Rogers, B Bookman, MA Millenson, MM Boente, M Rosenblum, N Litwin, S Ozols, RF
Citation: Rj. Schilder et al., Phase I trial of multiple cycles of high-dose chemotherapy supported by autologous peripheral-blood stem cells, J CL ONCOL, 17(7), 1999, pp. 2198-2207
Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsedor refractory CD20(+) B-cell non-Hodgkin's lymphoma
Authors: Witzig, TE White, CA Wiseman, GA Gordon, LI Emmanouilides, C Raubitschek, A Janakiraman, N Gutheil, J Schilder, RJ Spies, S Silverman, DHS Parker, E Grillo-Lopez, AJ
Citation: Te. Witzig et al., Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsedor refractory CD20(+) B-cell non-Hodgkin's lymphoma, J CL ONCOL, 17(12), 1999, pp. 3793-3803
Risultati: 1-7 |